News | April 20, 2009

RapidArc Used with Novalis Tx System Treats Head and Neck Cancer Patient

April 21, 2009 - A 51-year old female cancer patient from Switzerland has become the first patient outside the U.S. to be treated with RapidArc radiotherapy technology from Varian Medical Systems on a Novalis Tx platform for radiosurgery and radiotherapy.

Doctors at Inselspital, the Bern University Hospital, used the Novalis Tx platform from Varian and BrainLAB to treat a patient suffering simultaneous skin cancer of the nose and an aggressive nasopharyngeal cancer with image-guided IMRT (intensity modulated radiotherapy). The treatment was “very satisfactory” and compared favorably with conventional treatment techniques, according to professor Daniel M. Aebersold, chairman of radiation oncology, who said the patient is responding well to the treatment.

Rather than targeting tumors with radiation beams from fixed angles, the Novalis Tx unit with RapidArc capability rotates continuously around the patient performing radiotherapy or radiosurgery several times faster than is possible with conventional techniques, according to Varian.

"Our first case was particularly challenging due to the fact that two distinct tumor regions were to be treated using different dose prescriptions," said Aebersold. "The treatment was very quick and we were very impressed by the excellent conformity and good sparing of organs at risk compared to standard IMRT."

"By delivering advanced RapidArc treatments on a gold standard platform such as a Novalis Tx, we were able to combine speed with extremely high precision, to minimize the possibility of movement during treatment, which is particularly important bearing in mind the larger doses we are using."

For more information: www.varian.com

Related Content

Varian Receives FDA 510k Clearance for Halcyon Treatment System
Technology | Intensity Modulated Radiation Therapy (IMRT) | July 05, 2017
Varian Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Halcyon system,...
First New York Metropolitan Hospital Treats Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | July 03, 2017
Accuray Inc. and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS),...
IUCT Oncopole Installs First Radixact Radiotherapy System in France
News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017
Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in Toulouse, France,...
cervical and endometrial cancer, IMRT, intensity modulated radiation therapy, side effects, ASTRO 2016 study
News | Intensity Modulated Radiation Therapy (IMRT) | September 29, 2016
Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience...
non-small cell lung cancer, NSCLC, IMRT, toxicity, intensity modulated radiation therapy, 3-D CRT, ASTRO 2015
News | Lung Cancer | October 28, 2015
October 28, 2015 — An analysis of an international, cooperative-led trial of patients with locally advanced non-small
pediatric ependymoma patients, immediate post-surgical radiation therapy, Children's Oncology Group ACNS0121 trial, ASTRO 2015
News | Radiation Therapy | October 22, 2015
Outcomes for pediatric patients as young as 12 months with ependymoma who are treated with immediate post-operative...
post-prostatectomy IG-IMRT, image-guided intensity-modulated radiation therapy, toxicity, ASTRO, Practical Radiation Oncology
Feature | Intensity Modulated Radiation Therapy (IMRT) | October 06, 2015
A prospective study of guideline-based postoperative image-guided intensity modulated radiation therapy (IG-IMRT) in...
IMRT, chemo-radiation, oropharyngeal, head and neck cancer, combination, quality of life, study, University of Michigan
News | Intensity Modulated Radiation Therapy (IMRT) | August 14, 2015
Combining intensity-modulated radiotherapy (IMRT) with chemotherapy to treat locally advanced oropharyngeal (head and...
Overlay Init